Apyx Medical Corporation Announces Peer-Reviewed Clinical Publication Evaluating the Safety of Renuvion® Following Liposuction in Multiple Areas of the Body

Core Viewpoint - Apyx Medical Corporation announced the publication of a peer-reviewed article demonstrating the safety of its Renuvion technology for contracting subcutaneous soft tissue following liposuction, which supports its FDA 510(k) clearance for this application [1][2][3] Group 1: Publication and Analysis - The peer-reviewed article published in the Aesthetic Surgery Journal Open Forum evaluated the use of Renuvion in 483 patients treated post-liposuction across 1,184 body areas [1][2] - The analysis included data from six published retrospective studies, focusing on the safety and efficacy of Renuvion compared to liposuction alone [2][3] - The authors concluded that Renuvion did not present new or increased risks when used after liposuction, and the risks were consistent across different body areas [3] Group 2: Company Background and Technology - Apyx Medical Corporation specializes in advanced energy technology, particularly its Helium Plasma Technology products marketed as Renuvion in cosmetic surgery and J-Plasma in hospital surgical markets [4] - The company emphasizes its ability to provide controlled heat to tissue, enhancing surgical outcomes [4]